(Q35858331)

English

Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit

scientific article published on 31 March 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit (English)

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Ignacio I Wistuba

19

object named as

Ignacio Wistuba

1 reference

Europe PubMed Central

10 August 2017

PMC publication ID

author name string

Hartmut Koeppen

1

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Wei Yu

2

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Jiping Zha

3

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Ajay Pandita

4

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Elicia Penuel

5

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Linda Rangell

6

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Rajiv Raja

7

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Sankar Mohan

8

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Rajesh Patel

9

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Rupal Desai

10

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Ling Fu

11

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

An Do

12

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Vaishali Parab

13

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Xiaoling Xia

14

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Tom Januario

15

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Sharianne G Louie

16

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Ellen Filvaroff

17

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

David S Shames

18

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Marina Lipkind

20

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Jenny Huang

21

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Mirella Lazarov

22

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Vanitha Ramakrishnan

23

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Lukas Amler

24

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

See-Chun Phan

25

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Premal Patel

26

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Amy Peterson

27

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Robert L Yauch

28

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

language of work or name

0 references

publication date

31 March 2014

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

20

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

17

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

4488-4498

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

Targeting MET in cancer: rationale and progress

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

Role of MetMAb (OA-5D5) in c-MET active lung malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

MET signalling: principles and functions in development, organ regeneration and cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

Crosstalk in Met receptor oncogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

Ethnic differences and functional analysis of MET mutations in lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

Somatic mutations lead to an oncogenic deletion of met in lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

11 July 2018

Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

24 September 2018

Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

24 September 2018

Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

24 September 2018

EGF and HGF levels are increased during active HBV infection and enhance survival signaling through extracellular matrix interactions in primary human hepatocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

24 September 2018

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

24 September 2018

Increased hepatocyte growth factor in serum in acute graft-versus-host disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

24 September 2018

Serum interleukin-6, interleukin-8, hepatocyte growth factor, and nitric oxide changes during thoracic surgery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4504679

24 September 2018

The clinical significance of hepatocyte growth factor for non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24687921

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV

1 reference

https://pubmed.ncbi.nlm.nih.gov/24687921

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased circulating hepatocyte growth factor (HGF): a marker of epithelial ovarian cancer and an indicator of poor prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24687921

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-13-1836

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35858331&oldid=2249120142"